Targets › METAP2
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.
Cotranslationally removes the N-terminal methionine from nascent proteins. The N-terminal methionine is often cleaved when the second residue in the primary sequence is small and uncharged (Met-Ala-, Cys, Gly, Pro, Ser, Thr, or Val). (UniProt, P50579)
Open in Phaseline: the race on METAP2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| SynDevRx | Evexomostat (SDX-7320) MetAP2 inhibitor | METAP2 | Phase 1 | HR+/HER2-negative Breast Cancer | Dec 2026 |
HR+/HER2-negative Breast Cancer (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.